Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 2012. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically regarding changes in their interests in the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction details rather than financial performance metrics.
Material Changes
On May 4, 2012, several directors and officers purchased Ordinary Shares through the reinvestment of dividends within Individual Savings Accounts (ISAs). The transaction price was 1,446.798 pence per Ordinary Share. The specific share increases were:
- Sir Andrew Witty: 54 shares
- Mr S M Bicknell: 121 shares
- Mr E J Gray: 11 shares
- Mr D S Redfern: 25 shares
- Mrs V A Whyte: 21 shares
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance notification under Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the share price of 1,446.798 pence per Ordinary Share on May 4, 2012.
- Confirm the total number of shares held by the listed directors following these dividend reinvestments.
- Review the company's broader financial reports for the period to assess overall performance, as this filing contains no financial data.